BIOMAT Database Logo BIOMAT Database Logo

[Comment on the contribution by U. Beiteke et al. Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Second comment]. 1994

O Gefeller, and U Kleeberg, and K F Kölmel
Abteilung Medizinische Statistik, Universität Göttingen.

UI MeSH Term Description Entries
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D016899 Interferon-beta One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity. Interferon, Fibroblast,beta-Interferon,Fiblaferon,Interferon, beta,Interferon, beta-1,Interferon-beta1,beta-1 Interferon,Fibroblast Interferon,Interferon beta,Interferon beta1,Interferon, beta 1,beta 1 Interferon,beta Interferon

Related Publications

O Gefeller, and U Kleeberg, and K F Kölmel
[Comment on the contribution by U. Beiteke et al. Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. First comment].
March 1994, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
O Gefeller, and U Kleeberg, and K F Kölmel
[Comment on the contribution by A. Hauschild et al.: "Safety margins in excision of primary malignant melanoma"].
April 2002, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
O Gefeller, and U Kleeberg, and K F Kölmel
[Comment on the contribution by J. Petres et al. Effective lymph node dissection in primary malignant melanoma].
September 1996, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
O Gefeller, and U Kleeberg, and K F Kölmel
[Laparoscopic resection in Crohn disease. Comment on the contribution by U. Hildebrandt et al].
September 1996, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen,
O Gefeller, and U Kleeberg, and K F Kölmel
Comment on the contribution by Lampert et al.
September 2007, Journal of cardiovascular electrophysiology,
O Gefeller, and U Kleeberg, and K F Kölmel
[Adjuvant interferon therapy in malignant melanoma].
June 2007, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG,
O Gefeller, and U Kleeberg, and K F Kölmel
[Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls].
June 1993, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
O Gefeller, and U Kleeberg, and K F Kölmel
[Comment on the contribution by C. Garbe et al.: Combination of interferon-alpha with cytostatic drugs: promising therapeutic approach in metastatic melanoma].
November 1992, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
O Gefeller, and U Kleeberg, and K F Kölmel
Adjuvant interferon therapy for malignant melanoma: the debate.
November 2010, Chinese journal of cancer,
O Gefeller, and U Kleeberg, and K F Kölmel
[Comment on the contribution by Weigl CB et al. "Papillomatosis confluens et reticularis"].
May 2002, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
Copied contents to your clipboard!